JMIR Publications

ABSTRACT

Background:

Background:

Among women of reproductive age, Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine-metabolic disorder marked by hormonal imbalances (e.g., elevated LH/FSH ratios and AMH levels), chronic anovulation, insulin resistance, and altered ovarian morphology. These changes often result in functional, metabolic, and reproductive deficits that drastically reduce physical ability and quality of life. Although pharmaceuticals are frequently administered, non-pharmacological therapies, such as organized exercise, provide an essential all-encompassing strategy for reducing the severity of illness

Objective:

To evaluate changes in biochemical parameters, including LH, FSH, and AMH levels, following a structured exercise program in nulliparous women with polyendocrine metabolic ovarian syndrome To assess improvements in functional outcomes following a structured exercise program in nulliparous women with polyendocrine metabolic ovarian syndrome. To determine changes in radiological parameters, including ovarian volume and follicle count, following a structured exercise program in nulliparous women with polyendocrine metabolic ovarian syndrome. To compare pre- and post-intervention on biochemical, functional, and radiological outcomes in nulliparous women with PMOS after participation in the structured exercise program.

Methods:

Methods:

Study Design a two-group pre-test post-test randomized clinical trial. A total sample size of 52 nulliparous women aged 18–35 years, BMI > 25 kg/m meeting the modified Rotterdam criteria will be recruited and randomly clinically allocated into two groups of 26 participants each: Experimental Group (Group A) Receives standard pharmacological treatment combined with a 12-week structured exercise program (3 days/week) comprising aerobic training, High-Intensity Interval Training (HIIT), resistance training, and mind-body exercises (yoga/Pilates). The control group (Group B) receives standard pharmacological treatment alongside general patient education regarding diet, physical activity, and lifestyle modification. Outcome Measures Assessments will be conducted at baseline, week 0, and week 12 (post-intervention). Biochemical Markers: Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Anti-Müllerian Hormone (AMH). Radiological Parameters: Ovarian volume and via transabdominal/transvaginal ultrasonography. Functional Outcomes Evaluated Using the 6-Minute Walk Test (6MWT) and Timed Up and Go (TUG) test

Results:

The study results have not been obtained yet because data collection and the overall thesis work still in progress

Conclusions:

and also the conclusion has not been obtained yet because data collection and the overall thesis work still in progress Clinical Trial: Guidelines of the Declaration of Helsinki (revised 2024)7 and the National Ethical Guidelines for biomedical and Health Research involving Human Participants given by the Indian Council of Medical Research (2017) will be followed for the study. The study has been approved by the institutional ethics committee (IEC-3862) of Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana. The trial is also registered in the Clinical Trials Registry India (CTRI) under registration number CTRI/2026/09/117833 India. Written informed consent is obtained from all participants, and their confidentiality is maintained throughout the study.